18
Treatment
Table 5. Bioequivalence Information and Charts
a
Suboxone or
generic equivalent
(sublingual tablet)
Suboxone
or generic
equivalent
(sublingual film)
Zubsolv
(sublingual tablet)
Bunavail
(buccal film)
2mg bup/
0.5mg nal tablet
2mg bup/
0.5mg nal film
One 1.4mg bup/
0.36mg nal tablet
4mg bup/1mg nal
(Taken as: two 2mg
bup/0.5mg nal
tablets)
4mg bup/
1mg nal film
One 2.9mg bup/
0.71mg nal tablet
One 2.1mg bup/
0.3mg nal film
8mg bup/2mg nal
tablet
8mg bup/
2mg nal film
One 5.7mg bup/
1.4mg nal tablet
One 4.2mg bup/
0.7mg nal film
12mg bup/3mg nal
(Taken as: One and
a half 8mg bup/2mg
nal tablets or one
8mg bup/2mg nal
tablets plus two
2mg bup/2mg nal
tablets)
12mg bup/
3mg nal film
One 8.6mg bup/
2.1mg nal tablet
One 6.3mg bup/
1mg nal film
16mg bup/4mg nal
(Taken as:
Two 8mg bup/2mg
nal tablets)
16mg bup/4mg nal
(Taken as:
Two 8mg bup/2mg
nal films)
One 11.4mg bup/
2.9mg nal tablet
Two 4.2mg bup/
0.7mg nal films
24mg bup/6mg nal
(Taken as:
three 8mg bup/3mg
nal tablets)
24mg bup/6mg nal
(Taken as:
Two 12mg bup/3mg
nal films)
17.2mg bup/4.1mg
nal (Taken as: Two
8.6mg bup/2.1mg
nal tablets)
Two 6.3mg bup/
1mg nal films
a
Table content was derived from FDA labels. Labels and label updates can be accessed at
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
b
e recommended dose of SUBLOCADE following induction and dose adjustment with
transmuscosal buprenorphine is 300mg monthly for the first two months followed by a
maintenance dose of 100mg monthly. e maintenance dose may be increased to 300mg
monthly for patients who tolerate the 100mg dose, but do not demonstrate a satisfactory
clinical response, as evidenced by self-reported illicit opioid use or urine drug screens positive
for illicit opioid use.
c
In a pharmacokinetic study, the 16mg/4mg dose of CASSIPA showed comparable
relative bioavailability of buprenorphine and naloxone compared with the same dose of
buprenorphine/naloxone administered sublingually, as two 8mg/2mg sublingual films.
